Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674219 · ClinicalTrials.gov registry record · Phase 3
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
A Phase 3 study of Obsessive - Compulsive Disorder and Generalized Anxiety Disorder, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT00674219: Completed Phase 3 study of Obsessive - Compulsive Disorder and Generalized Anxiety Disorder, sponsored by University of California, Los Angeles.
NCT00674219 is a Phase 3 study of Obsessive - Compulsive Disorder and Generalized Anxiety Disorder that has completed, run by University of California, Los Angeles. The registered enrollment target is 17 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674219, a Phase 3 study of Obsessive - Compulsive Disorder and Generalized Anxiety Disorder, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. Because glutamatergic hyperactivity in frontal and frontal-subcortical circuits may play a role in the symptomatic expression of OCD, and possibly GAD, agents that reduce glutamatergic neurotransmission should provide unique anti-stress and anti-obsessional benefits. Memantine is a specific, uncompetitive antagonist at the NMDA receptor that blocks sustained activation of the NMDA receptor by high concentrations of glutamate under pathological conditions but rapidly leaves the NMDA channel upon transient physiological activation by low concentrations of glutamate.
Primary Outcome
Participants in the OCD group were rated using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), a standard measure of obsessive-compulsive disorder (OCD) severity in pharmacotherapy studies. It is administered by a trained rater. It comprises 10 items assessing OCD symptoms (e.g. time spent, degree of control, severity). Each item is scored on a scale from 0 (not present) to 4 (severe) \[total score range = 0-40\] over the previous week. The higher the number on the Y-BOCS, the more severe th
Conditions Studied
Interventions
- DRUG Memantine
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
What the finished NCT00674219 record still lists
NCT00674219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Memantine is the first listed.
NCT00674219 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00674219 about?
NCT00674219 is a clinical study titled "Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder". The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. Because glutamatergic hyperactivity in frontal and frontal-su...
What is the current status of trial NCT00674219?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2005-05. Estimated completion is 2008-01.
What conditions does trial NCT00674219 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder, Generalized Anxiety Disorder.
What interventions are being tested in trial NCT00674219?
The interventions under investigation include: Memantine (DRUG).
Who is sponsoring clinical trial NCT00674219?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00674219 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00674219's enrollment target sits among peer trials
17 71st of 84 higher than 14 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
COMPLETED · Phase 3
-
Treatment of Obsessive-Compulsive Disorder (OCD) in Children
COMPLETED · Phase 3
-
Treatment of Obsessive Compulsive Disorder in Children
COMPLETED · Phase 3
-
Family Based Treatment of Early Childhood Obsessive Compulsive Disorder
COMPLETED · Phase 3
-
Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder
COMPLETED · Phase 3
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia